Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
SHR-A2102
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
- NCT05701709 ↗
- Recruiting
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Focused
We haven't built an HCP commentary report on SHR-A2102 (SHR-A2102 in Advanced Solid Tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SHR-A2102 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of SHR-A2102 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- SHR-A2102
- Arms
- SHR-A2102 · Experimental
- Enrollment
- 395 (estimated)
- Primary outcomes
- Number of participants with adverse events
- Maximum tolerated dose (MTD)
- Recommended Phase 2 dose (RP2D)
- Dose Limiting Toxicity (DLT)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Start
- Apr 6, 2023
- Primary completion
- Aug 31, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05701709 · updated Jul 22, 2025
Publications
linked from the registry- Zhong R, Hong H, Yan M, Wang Q, Zhang Y, Lan Q, Luo Y, Zhang L, Xu H, Guo S, Guo W, Ma J, Zhang L, Wu L, Liu Z, He W, Sun Y, Chen K, Huang J, Han G, Nian W, Zhang M, Ren S, Qiao R, Li X, Yu M, Hu J, Huang Y, Song L, Shi W, Zhong H. SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. Lancet Oncol. 2026 Sep;27(9):1146-1157. doi: 10.1016/S1470-2045(26)00238-X. PubMed 42636836